# US 2014/0194477 A1 · Kinase protein binding inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194477 A1
- Document ID: US20140194477A1
- Status: Published application
- Kind: A1
- Application number: 14/048,963
- Filed: 2013-10-08
- Published: 2014-07-10
- Earliest claimed: 2011-04-08
- Assignees: Roswell Park Cancer Institute
- Applicants: Roswell Park Cancer Institute
- Inventors: William G. Cance; Vita Golubovskaya; Elena V. Kurenova
- Web page: https://patentgrep.com/patent/US20140194477A1

## CPC

- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer.

## Claims

### Claim 1

A method of treating a subject suffering from or susceptible to a brain cancer comprising administering to the subject in need thereof a therapeutically effective amount of the compound C4 or Y15.

### Claim 2

(canceled)

### Claim 3

A method of treating a subject suffering from or susceptible to melanoma comprising administering to the subject in need thereof a therapeutically effective amount of the compound C4 or Y15.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1 further comprising administering to the subject in need thereof a therapeutically effective amount of temozolomide.

### Claim 6 (depends on 5)

The method of claim 5 wherein the compounds are administered separately.

### Claim 7 (depends on 5)

The method of claim 5 wherein the compounds are administered concurrently.

### Claim 8 (depends on 5)

The method of claim 5 wherein the compounds are administered in a single-dose form.

### Claim 9

A composition comprising temozolomide and a second compound Wherein the second compound is:
C4: N′-[(4-chlorophenyl)methyl]-N,N-dimethyl-N′-pyridin-2-yl-ethane-1,2-diamine (NSC 409949; Sigma C1915, Suprastin; chloropyramine hydrochloride); or
Y15: 1,2,4,5-benzenetetraamine tetrahydrochloride.

### Claim 10

The composition further comprising a pharmaceutically acceptable carrier.

### Claim 11 (depends on 9)

The composition of claim 9 in a single-dose formulation.

### Claim 12

(canceled)

### Claim 13

(canceled)